These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 23952551)

  • 41. Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion.
    Iversen PL; Mata J; Tracewell WG; Zon G
    Antisense Res Dev; 1994; 4(1):43-52. PubMed ID: 8061515
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fatty Acid-Modified Gapmer Antisense Oligonucleotide and Serum Albumin Constructs for Pharmacokinetic Modulation.
    Hvam ML; Cai Y; Dagnæs-Hansen F; Nielsen JS; Wengel J; Kjems J; Howard KA
    Mol Ther; 2017 Jul; 25(7):1710-1717. PubMed ID: 28641935
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Toxicological properties of several novel oligonucleotide analogs in mice.
    Henry SP; Zuckerman JE; Rojko J; Hall WC; Harman RJ; Kitchen D; Crooke ST
    Anticancer Drug Des; 1997 Jan; 12(1):1-14. PubMed ID: 9051110
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phosphorothioate oligonucleotides: effectiveness and toxicity.
    Iannitti T; Morales-Medina JC; Palmieri B
    Curr Drug Targets; 2014; 15(7):663-73. PubMed ID: 24655142
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antisense phosphorothioate oligonucleotides: selective killing of the intracellular parasite Leishmania amazonensis.
    Ramazeilles C; Mishra RK; Moreau S; Pascolo E; Toulmé JJ
    Proc Natl Acad Sci U S A; 1994 Aug; 91(17):7859-63. PubMed ID: 8058724
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides.
    Iwamoto N; Butler DCD; Svrzikapa N; Mohapatra S; Zlatev I; Sah DWY; Meena ; Standley SM; Lu G; Apponi LH; Frank-Kamenetsky M; Zhang JJ; Vargeese C; Verdine GL
    Nat Biotechnol; 2017 Sep; 35(9):845-851. PubMed ID: 28829437
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Splice-switching efficiency and specificity for oligonucleotides with locked nucleic acid monomers.
    Guterstam P; Lindgren M; Johansson H; Tedebark U; Wengel J; El Andaloussi S; Langel U
    Biochem J; 2008 Jun; 412(2):307-13. PubMed ID: 18271753
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of different chemically modified oligodeoxynucleotides on immune stimulation.
    Zhao Q; Temsamani J; Iadarola PL; Jiang Z; Agrawal S
    Biochem Pharmacol; 1996 Jan; 51(2):173-82. PubMed ID: 8615886
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nuclease resistance and antisense activity of modified oligonucleotides targeted to Ha-ras.
    Monia BP; Johnston JF; Sasmor H; Cummins LL
    J Biol Chem; 1996 Jun; 271(24):14533-40. PubMed ID: 8662854
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of Repeated Complement Activation Associated with Chronic Treatment of Cynomolgus Monkeys with 2'-O-Methoxyethyl Modified Antisense Oligonucleotide.
    Shen L; Engelhardt JA; Hung G; Yee J; Kikkawa R; Matson J; Tayefeh B; Machemer T; Giclas PC; Henry SP
    Nucleic Acid Ther; 2016 Aug; 26(4):236-49. PubMed ID: 27140858
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synthesis and cellular activity of stereochemically-pure 2'-O-(2-methoxyethyl)-phosphorothioate oligonucleotides.
    Li M; Lightfoot HL; Halloy F; Malinowska AL; Berk C; Behera A; Schümperli D; Hall J
    Chem Commun (Camb); 2017 Jan; 53(3):541-544. PubMed ID: 27966701
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Short antisense oligonucleotides with novel 2'-4' conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals.
    Seth PP; Siwkowski A; Allerson CR; Vasquez G; Lee S; Prakash TP; Wancewicz EV; Witchell D; Swayze EE
    J Med Chem; 2009 Jan; 52(1):10-3. PubMed ID: 19086780
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dose-dependent pharmacokinetic profiles of 2'-O-methyl phosphorothioate antisense oligonucleotidesin mdx mice.
    Verhaart IE; Tanganyika-de Winter CL; Karnaoukh TG; Kolfschoten IG; de Kimpe SJ; van Deutekom JC; Aartsma-Rus A
    Nucleic Acid Ther; 2013 Jun; 23(3):228-37. PubMed ID: 23634945
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetics of antisense oligonucleotides.
    Agrawal S; Temsamani J; Galbraith W; Tang J
    Clin Pharmacokinet; 1995 Jan; 28(1):7-16. PubMed ID: 7712663
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vivo delivery of antisense oligonucleotides in pH-sensitive liposomes inhibits lipopolysaccharide-induced production of tumor necrosis factor-alpha in rats.
    Ponnappa BC; Dey I; Tu GC; Zhou F; Aini M; Cao QN; Israel Y
    J Pharmacol Exp Ther; 2001 Jun; 297(3):1129-36. PubMed ID: 11356938
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of bovine milk extracellular vesicles for the delivery of locked nucleic acid antisense oligonucleotides.
    Grossen P; Portmann M; Koller E; Duschmalé M; Minz T; Sewing S; Pandya NJ; van Geijtenbeek SK; Ducret A; Kusznir EA; Huber S; Berrera M; Lauer ME; Ringler P; Nordbo B; Jensen ML; Sladojevich F; Jagasia R; Alex R; Gamboni R; Keller M
    Eur J Pharm Biopharm; 2021 Jan; 158():198-210. PubMed ID: 33248268
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides.
    Østergaard ME; De Hoyos CL; Wan WB; Shen W; Low A; Berdeja A; Vasquez G; Murray S; Migawa MT; Liang XH; Swayze EE; Crooke ST; Seth PP
    Nucleic Acids Res; 2020 Feb; 48(4):1691-1700. PubMed ID: 31980820
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms.
    Chiang MY; Chan H; Zounes MA; Freier SM; Lima WF; Bennett CF
    J Biol Chem; 1991 Sep; 266(27):18162-71. PubMed ID: 1680858
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antisense c-myc and immunostimulatory oligonucleotide inhibition of tumorigenesis in a murine B-cell lymphoma transplant model.
    Smith JB; Wickstrom E
    J Natl Cancer Inst; 1998 Aug; 90(15):1146-54. PubMed ID: 9701364
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oligonucleotide treatment of ras-induced tumors in nude mice.
    Wickstrom E
    Mol Biotechnol; 2001 May; 18(1):35-55. PubMed ID: 11439698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.